Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$803K Sell
2,282
-49,080
-96% -$17.5M 0.01% 494
2025
Q4
$16.8M Sell
51,362
-148,956
-74% -$47.3M 0.11% 133
2025
Q3
$56.5M Buy
200,318
+8
+0% +$2.32K 0.4% 57
2025
Q2
$55.9M Buy
200,310
+19,411
+11% +$5.5M 0.49% 43
2025
Q1
$56.4M Buy
180,899
+177,777
+5,694% +$52.5M 1.08% 25
2024
Q4
$814K Buy
3,122
+1,448
+86% +$430K 0.01% 270
2024
Q3
$539K Buy
+1,674
New +$548K 0.01% 293
2024
Q1
Sell
-11,290
Closed -$3.25M 496
2023
Q4
$3.25M Buy
+11,290
New +$3.08M 0.13% 118
2023
Q1
Sell
-1,665
Closed -$437K 261
2022
Q4
$437K Buy
+1,665
New +$446K 0.06% 185

Other funds holding AMGN

Marex Group's AMGN Position: Q1 2026 in Review

Marex Group reduced its Amgen (AMGN) stake by 96% in Q1 2026, selling an estimated $17.5M and leaving 2,282 shares worth $803K. The position accounts for 0.01% of the portfolio, ranked #494.

Marex Group first reported a position in AMGN in Q4 2022 and has held it in 9 quarters since. The position peaked at $56.5M in Q3 2025. 3,126 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

  • Marex Group held 2,282 shares of Amgen worth $803K as of Q1 2026.
  • Marex Group sold 49,080 Amgen shares in Q1 2026, an estimated $17.5M.
  • Amgen made up 0.01% of Marex Group's portfolio in Q1 2026, its #494 holding.
  • Marex Group first reported a position in Amgen in Q4 2022 and has held it in 9 quarters since.
  • Marex Group's Amgen position peaked at $56.5M in Q3 2025.
  • 3,126 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on Marex Group's 13F filing for Q1 2026, filed 13 May 2026.